Supplied for research purposes only. These peptides are laboratory reagents intended for qualified researchers and educational institutions. Not for human use, animal use, or clinical application.
BPC-157 Storage & Stability Datasheet
🖨️ NovaVitality Technical Datasheet
Document ID: NV-DS-BPC157-001
Version: 1.0
Effective Date: 10 December 2025
Product: BPC-157 Research Peptide (RUO)
1. Product Overview
| Parameter | Specification |
| INN (Proposed) | BPC-157 (Body Protection Compound-157) |
| CAS Status | 137525-51-0 (assigned) |
| Molecular Formula | C₆₂H₉₈N₁₆O₂₂ |
| Molecular Weight | 1411.55 g/mol (monoisotopic, Ac–NH₂ form) |
| Sequence | Ac-Gly-Glu-Pro-Pro-Pro-Pro-Ser-Ile-Pro-Asp-Ser-Ser-Asp-Gly-Arg-Ala-NH₂ |
| Receptor Profile | Receptor-agnostic; modulates integrin αvβ3, VEGFR2, GRP78, and NO pathways |
| Form Supplied | Lyophilised solid (white to off-white powder) |
| Purity (HPLC-UV) | ≥98% (isocratic elution, C18, 220 nm) |
| Endotoxin | <0.5 EU/mg (LAL kinetic assay) |
| Residual Solvents | Meets ICH Q3C Class 3 limits (≤5000 ppm total) |
| RUO Status | For research use only — not for human or veterinary use |
2. Recommended Storage Conditions
✅ Unopened (Lyophilised)
| Condition | Stability Duration | Notes |
| −20°C, desiccated, dark | ≥36 months | Exceptional long-term stability due to Ac/NH₂ protection. Use airtight secondary container with desiccant. |
| 2–8°C (refrigerated) | ≤12 months | Suitable for active lab use; monitor for cake collapse (indicates moisture uptake). |
| Room Temp (≤25°C) | ≤14 days | Stable for transit. Avoid humidity >60% RH. |
📌 BPC-157 is among the most stable therapeutic-class peptides — lyophilised form shows <2% degradation after 3 years at −20°C (internal stability study, NV-2024-087).
✅ Reconstituted (Solution)
| Solvent | Short-Term (2–8°C) | Long-Term (−80°C) | Notes |
| 0.9% NaCl (sterile saline) | ≤14 days | ≥12 months (aliquoted) | Preferred — mimics physiological conditions; minimal degradation |
| Bacteriostatic water (0.9% BA) | ≤10 days | ≥9 months (aliquoted) | Acceptable; benzyl alcohol does not impair bioactivity |
| 0.1% acetic acid | ≤72 hours | ≤3 months | Not recommended — accelerates Asp-Pro cleavage at positions 10–11 & 13–14 |
⚠️ Critical:
– BPC-157 tolerates ≤5 freeze–thaw cycles with <5% potency loss (cAMP/VEGF assay validation).
– Use standard polypropylene tubes (no low-bind required — minimal adsorption).
– Avoid glass vials (pH shift from silanol groups may reduce stability).
3. Stability Indicators & Degradation Risks
| Risk Factor | Effect on BPC-157 | Detection Method |
| Moisture exposure | Minimal hydrolysis (Ac/NH₂ protects termini) | HPLC: new peak at ~8 min (RT shift) |
| Acidic pH (<4.0) | Asp-Pro cleavage (Asp¹⁰–Pro¹¹, Asp¹³–Pro¹⁴) | LC-MS: −113 Da (Pro), −226 Da (di-Pro) fragments |
| Oxidation (Met⁰ absent) | Very low risk (no Met/Cys/Trp) | Not typically observed |
| Alkaline pH (>8.5) | Deamidation (Asn absent; Asp is stable) | Rare — monitor Glu isomerisation (HPLC peak splitting) |
| Repeated freeze–thaw | Slight aggregation (>5 cycles) | DLS (>100 nm particles), reduced solubility |
🔬 Tip: For long-term in vivo studies, prepare 1–2 week aliquots in saline and store at 4°C — BPC-157 remains >95% intact.
4. Reconstitution Protocol (Best Practice)
- Equilibrate vial to room temp (10–15 min) before opening.
- Centrifuge briefly (3 sec) to collect powder.
- Add sterile 0.9% NaCl slowly down vial wall (e.g., 2 mL for 10 mg → 5 mg/mL stock).
- Gently swirl — full dissolution typically in <60 sec (no vortexing needed).
- No warming or sonication required.
- Filter through 0.22 µm PVDF if for in vivo or primary cell use.
- Aliquot (e.g., 100 µL), seal, and store at −80°C or 4°C (for ≤14-day use).
5. Analytical Verification (Post-Storage)
| Test | Acceptance Criteria | When to Run |
| HPLC Purity | ≥95% main peak | After >12 months storage, or pre-critical assay |
| MS Identity | Observed MW 1411.5 ±1.0 Da | Annually, or after suspected contamination |
| Endotoxin | <1.0 EU/mL in solution | Before in vivo or immune cell studies |
| Bioactivity (Optional) | ≥90% activity vs. fresh CoA (VEGF ELISA in HUVECs) | For longitudinal wound-healing studies |
6. References & Compliance
- Šebečić B et al. J Physiol Pharmacol. 1996;47(2):165–172. PMID: 8877278
- Sikirić P et al. World J Gastroenterol. 2017;23(19):3381–3401. DOI: 10.3748/wjg.v23.i19.3381
- ICH Q1A(R2): Stability Testing of New Drug Substances
- USP <1079>: Good Storage and Distribution Practices
- MHRA Guidance on Unlicensed Substances in Research (2024)
7. Support & Documentation
📧 Technical queries: [email protected]
🔒 This datasheet is for informational purposes only. NovaVitality makes no warranties, express or implied, regarding fitness for a particular purpose. Researchers bear full responsibility for validation in their experimental context.
